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Abstract
Drug-drug interactions (DDIs) can lead to serious and potentially lethal adverse events. In recent years, several drugs have
been withdrawn from the market due to interaction-related adverse events (AEs). Current methods for detecting DDIs rely
on the accumulation of sufficient clinical evidence in the post-market stage – a lengthy process that often takes years,
during which time numerous patients may suffer from the adverse effects of the DDI. Detection methods are further
hindered by the extremely large combinatoric space of possible drug-drug-AE combinations. There is therefore a practical
need for predictive tools that can identify potential DDIs years in advance, enabling drug safety professionals to better
prioritize their limited investigative resources and take appropriate regulatory action. To meet this need, we describe
Predictive Pharmacointeraction Networks (PPINs) – a novel approach that predicts unknown DDIs by exploiting the network
structure of all known DDIs, together with other intrinsic and taxonomic properties of drugs and AEs. We constructed an
856-drug DDI network from a 2009 snapshot of a widely-used drug safety database, and used it to develop PPIN models for
predicting future DDIs. We compared the DDIs predicted based solely on these 2009 data, with newly reported DDIs that
appeared in a 2012 snapshot of the same database. Using a standard multivariate approach to combine predictors, the PPIN
model achieved an AUROC (area under the receiver operating characteristic curve) of 0.81 with a sensitivity of 48% given
a specificity of 90%. An analysis of DDIs by severity level revealed that the model was most effective for predicting
‘‘contraindicated’’ DDIs (AUROC=0.92) and less effective for ‘‘minor’’ DDIs (AUROC=0.63). These results indicate that
network based methods can be useful for predicting unknown drug-drug interactions.
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Introduction
Adverse drug-drug interactions (DDIs) are a serious health
threat that can result in significant morbidity and mortality. In
recent years, several drugs have been withdrawn from the market
because of serious interaction-related adverse events (AEs). For
example, the antihistamine drug astemizole (Hismanal) and the
gastrointestinal-disorders drug cisapride (Propulsid) were with-
drawn from the market in 1999 and 2000, respectively, after it was
determined that each could cause fatal arrhythmias when given in
combination with certain other drugs [1,2]. Similarly, the
hypertension drug mibefradil (Posicor) was withdrawn from the
market in 1998 because of interactions with a number of other
drugs [3].
Drug-drug interactions may be categorized by various criteria,
two important ones being the severity level and the underlying
DDI mechanism. In terms of severity, DDIs are often categorized
into minor, moderate and severe (or, major) [4]. Minor DDIs are
considered of slight clinical significance and typically only call for
routine patient monitoring, moderate DDIs have a higher clinical
significance and may require dosage changes and closer monitor-
ing, and major DDIs can lead to serious adverse effects and should
typically be avoided. In terms of mechanism, DDIs can be broadly
categorized as either pharmacokinetic or pharmacodynamic [4–
7]. Pharmacokinetic DDIs occur when one drug interferes with the
absorption, distribution, metabolism, or elimination of another
drug, leading to changes in the plasma concentration of the
affected drug. One of the largest groups of pharmacokinetic
interactions are those caused by the inhibition or induction of
cytochrome P450 (CYP) isozymes, which are involved in the
metabolism of many drugs [4,5]. Pharmacodynamic interactions
occur when one drug interferes with a second drug at a target site,
leading to additive or subtractive effects for the involved drugs
[4,7]. Although important, pharmacodynamic interactions make
up a smaller class than pharmacokinetic interactions.
Ideally, the interactions of a new drug with existing drugs could
be predicted in the early stages of discovery and development.
Traditionally, early stage predictions have focused on pharmaco-
kinetic DDIs and include a variety of in silico [8–11] and in vitro
methods [5,12–15]. Presently, for many types of pharmacokinetic
interactions, early stage prediction can be highly sensitive and
specific. On the other hand, for pharmacodynamic DDIs,
although early-stage prediction is also routinely conducted, it is
comparatively less effective [16,17]. In the later pre-market stages,
in vivo experiments [18] and clinical trials are employed to check
the most important interactions predicted in the early stages.
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61468Notwithstanding this wide range of activities, many important
DDIs can go undetected in the pre-market phase, as evidenced by
interaction-related post-market warnings and withdrawals.
For the many DDIs that go undetected in the pre-market phase,
early detection during the post-market phase could lead to the
prevention of many potential AEs, either through the addition of
an interaction warning on the drug label, or in extreme cases
through drug withdrawal. A number of statistical methods exist for
detecting whether the combination of two drugs is associated with
an increased risk of certain AEs. These methods analyze post-
market data, such as spontaneous reports, insurance claim
databases or electronic medical records [19–22]. In order to
identify potential safety issues, these detection methods rely on
waiting for sufficient post-market evidence to accumulate –
a process that can take years, during which time numerous people
may be affected by the adverse interaction. Detection methods are
further hindered by the vastness of the space of possible drug-drug-
AE combinations. Therefore, there is a practical need for
predictive tools that can identify potential DDIs years in advance.
To meet this need, we propose Predictive Pharmacointeraction
Networks (PPINs). PPINs exploit the network structure formed by
the set of known DDIs, as well as various intrinsic and taxonomic
properties of drugs, in order to predict unknown DDIs. PPINs
work by constructing a network of known DDIs, where ‘‘nodes’’
represent drugs and ‘‘edges’’ represent the known interactions
between drugs. A predictive model is developed to predict the
unknown edges, or DDIs. Such a ‘‘link-prediction’’ approach has
been used in other applications, such as social, metabolic or food
networks [23,24]. Network analysis is well suited for the medical
and pharmacological domain, where complex relationships exist
among various entities, such as drugs, targets, and diseases [25–
28]. A number of recent pharmacological studies have proposed
interesting applications of network analysis, including character-
izations of the network structure formed by known drug-drug
interactions [29,30]. Our prior work has focused on developing
network-based models to predict unknown drug-adverse event
associations [31]. To our knowledge, the current study is the first
to use network-based models for predicting unknown DDIs. While
detection of unknown AEs is a difficult challenge, detection of
unknown DDIs is far more challenging as it involves relying on
sufficient evidence accumulating within a much smaller sub-
population that is simultaneously exposed to both drugs and
presenting with the relevant AE. Since DDI’s can be more difficult
to detect than AE’s, it is even more critical to develop effective
methods for predicting DDIs years in advance. Prediction of DDIs
is a challenging and unique problem that requires a tailored set of
methods and predictors. Whereas in predictive bipartite drug-AE
networks, each drug node can only be connected to an AE node,
in the DDI network each drug node may potentially be connected
with every other node in the network.
In this study, we evaluate the performance of a predictive
network model using a simulated-prospective validation based on
two chronologically separated snapshots of a widely used drug
safety database. This validation method preserves the historical
order in which the data became available, thereby enabling
a realistic assessment of the model’s predictive power. The
computational approach proposed here is intended as a comple-
mentary hypothesis-generation tool to help drug safety experts
identify potential drug-drug interactions. The predicted DDIs can
be used to guide follow-up investigation by drug safety experts.
Results
We begin with an overview of the PPIN approach (Fig. 1),
followed by a more detailed methodological account. To construct
the PPIN, we integrated data from multiple sources, including
DDI data, drug taxonomic data and intrinsic drug properties.
Based on a 2009 snapshot of a widely used drug safety database,
we constructed a network representation of all known DDIs,
where each node represents a drug, and each edge connecting two
nodes represents a known interaction between those two drugs.
Next, we used these data to construct a set of covariates and to
develop predictive logistic regression (LR) and generalized linear
mixed (GLM) models. These models predicted the probabilities for
all the non-edges of the 2009 network and those with the highest
probabilities formed the model’s top predictions for unknown
DDIs. We performed a simulated prospective evaluation of the
model’s predictive performance by comparing these predictions
with the set of newly reported DDIs that appeared in a 2012
version of the same drug safety database, and were not present in
the 2009 snapshot.
All the above steps were also carried out for three sub-networks
of the DDI network, namely the sub-networks induced by the
‘‘minor’’, ‘‘major’’ and ‘‘contraindicated’’ DDIs. (Following
standard network theory terminology, the subgraph induced by
a set of edges consists of those edges together with any vertices that
are their endpoints.).
Data Description
Fig. 2 provides a visualization of the DDI network (produced
using the Cytoscape visualization tool, www.cytoscape.org). The
data for constructing this network were obtained from the
following sources: DDIs were extracted from two chronologically
separated snapshots of Multum Vantage Rx, a widely used drug
safety database. This database contains a variety of clinical
information about drug products and diseases, including drug-
drug interactions, drug-disease interactions, allergies, dosing
information, and so on (http://www.multum.com/
VantageRxDB.htm). In this study, we only used the Vantage Rx
information on drug-drug interactions. The two snapshots used in
the study contained all reported DDIs of all FDA-approved drugs
as of October 2009 and March 2012, respectively. The taxonomic
and intrinsic drug properties were extracted from World Health
Organization Anatomical Therapeutic Chemical Classification
System (ATC) (www.whocc.no/atc) and DrugBank (http://www.
drugbank.ca/), respectively. Generic names were used to uniquely
represent drugs and to perform data integration. A list of
synonyms from NCGC Pharmaceutical Collection (NPC) [32]
was used to identify the different forms of generic names that
referred to a common ‘‘active pharmaceutical ingredient’’ (API).
After integrating the DDI data from the 2009 snapshot with the
DrugBank and ATC drug data, we identified 856 unique drugs
(APIs) for which valid data was available in all three databases.
The 2009 data contained 55,560 DDIs formed by these drugs.
The 2009 DDI network, thus, consisted of 856 nodes (drugs),
55,560 edges (DDIs) and 310,380 non-edges (pairs that were not
known to form DDIs in 2009). The known DDIs in the training set
made up 15.2% of all combinatorially possible DDIs. The 2012
DDI data snapshot reported 4,401 new DDIs among these 856
drugs (proportion of new DDIs in the validation set: 1.4% of all
combinatorially possible DDIs that were not reported as DDIs in
the 2009 dataset). Fig. 2A shows the DDIs contained in the 2009
safety database snapshot, while Fig. 2B shows the DDIs newly
reported in the 2012 snapshot. In both parts of Fig. 2 node size is
proportional to the node degree in the 2009 DDI network. Some
Network-Based Prediction of Drug Interactions
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e61468of the drugs with high degree in 2009 are labeled for illustration
purposes. As seen in Fig. 2B, many of the DDIs newly reported
during 2009–2012 involved drugs that were already highly
connected in 2009 (although a few drugs with small degree in
2009 had a notably large number of newly reported DDIs).
The 2009 sub-network induced by the set of ‘‘minor’’ DDIs (i.e.
the minor-DDI sub-network) consisted of 696 drugs and 4,221
DDIs. In 2012, there were 271 newly reported ‘‘minor’’ DDIs
among those drugs. The 2009 sub-network induced by the set of
‘‘major’’ DDIs (i.e. the major-DDI sub-network) consisted of 718
drugs and 7,263 DDIs. In 2012, there were 794 newly reported
‘‘major’’ DDIs among those drugs. The 2009 sub-network induced
by the set of ‘‘contraindicated’’ DDIs consisted of 491 drugs and
2,323 DDIs. In 2012, there were 122 newly reported ‘‘contra-
indicated’’ DDIs among those drugs.
Figure 1. Overview of the PPIN approach for predicting drug-drug interactions (DDIs). Beginning on the left, data were integrated from
multiple sources, including safety data (two snapshots of known DDIs from 2009 and 2012), taxonomic data (ATC taxonomy of drugs), and data
related to the intrinsic properties of drugs (chemical substructures). Next, a network representation of the DDIs contained in the 2009 database
snapshot was constructed from which a collection of network, taxonomic and intrinsic covariates were derived. These covariates were used to
develop a predictive model based solely on the 2009 data that predicted new, unknown drug-drug interactions. These predictions were evaluated
against the newly reported DDIs that appeared in the 2012 data.
doi:10.1371/journal.pone.0061468.g001
Figure 2. A visualization of the DDI network. (A) The DDIs present in the 2009 training dataset are shown in blue. (B) The DDIs newly reported in
the 2012 validation dataset are shown in red. In both parts, the size of each node is proportional to the node degree in the 2009 network. Some of
the most highly-connected drugs are labeled for illustrative purposes.
doi:10.1371/journal.pone.0061468.g002
Network-Based Prediction of Drug Interactions
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e61468Using the 2009 DDI network we derived a number of network,
taxonomic and intrinsic covariates (Table S1) corresponding to the
drug pairs. The network covariates encode purely structural
information contained in the DDI network, the taxonomic
covariates encode information related to the ATC categories of
drugs, while the intrinsic covariates encode information related to
the molecular substructures of drugs. Three of the network
covariates - degree_prod, betw_prod, and cccnw_max - aimed to
capture, respectively, the popularity, centrality, and network
clustering, which are widely used statistics in network analysis
[33]. The remaining covariates aimed to capture the similarity (or
dissimilarity) between the two drugs in terms of their network
properties (jackard, jackard_max2_mean), taxonomic properties
(atc_min, atc_min_prod), or chemical properties (str_jackard,
str_max_prod). The similarity-based covariates are either 0
th or
1
st order: the computation of the 0
th order covariates relies only on
the properties of the two drugs forming the pair (jackard, atc_min,
str_jackard), whereas the computation of the 1
st order covariates
relies on the properties of the two drugs forming the pair as well as
on the properties of their network neighbors.
The above covariates were also computed for the 2009 minor-
DDI, major-DDI, and contraindicated-DDI sub-networks.
Predictive Performance
We began our analysis by performing univariate LR analysis of
all covariates. Table S2 shows the results of this analysis, including
parameter estimates, P values, and the AUROC achieved in the
training set. Fig. 3A shows the validation set ROC curves and
AUROC values for six similarity-based covariates. The best
univariate performance was achieved by the 1
st order network
covariate jackard_max2_mean (validation set AUROC 0.779),
followed by 0
th order network covariate jackard (0.746), 1
st order
taxonomic covariate atc_min_prod (0.742), 0
th order intrinsic
covariate str_jackard (0.62) and 0
th order taxonomic covariate
atc_min (0.53). Likewise, Fig. 3B shows the ROC curves and the
validation set AUROCs for three non-similarity covariates.
We performed a systematic search over all subsets of covariates
to identify multivariate LR and GLM models with improved
prediction performance. Fig. 3C shows the ROC curves and
AUROC values for two such models. A parsimonious LR model
consisting of the three 1
st order similarity covariates (model LR3,
Table S3) achieved a validation set AUROC of 0.794. A GLM
model that also includes 0
th order and non-similarity covariates
(model GLM8, Table S4) achieved a small but significant
improvement over LR3 in terms of AUROC (AUROC=0.807,
p-value from comparison of LR3 and GLM8 ROC curves
,0.0001). For this model, the sensitivity was 0.11, 0.34, and
0.48, given a specificity of 0.99, 0.95, and 0.90, respectively. As is
often the case with predicting such rare phenomena, high
specificity and sensitivity can still be associated with low PPV. At
a specificity of 0.99, the PPV of the GLM8 model was 13.5% and
the model lift (i.e. the fold-reduction in the search space of possible
DDIs) was 9.6. The LR3 model achieved slightly higher PPV and
lift values at a specificity 0.99 (15% and 10.7, respectively). Fig. 3D
shows the ROC curves of model LR3 for the minor-DDI, major-
DDI and contraindicated-DDI sub-networks. The respective
AUROCs of these three sub-networks were 0.63, 0.81, and 0.92.
The results obtained for the DDI network indicate that
multivariate LR and GLM models achieved a small AUROC
improvement over the best performing covariate (jackard_max2_-
mean) and no PPV improvement at very high specificity levels (e.g.
above 99%). A close inspection of these multivariate models
reveals that they are dominated by the covariate jackard_max2_-
mean; the remaining covariates can only slightly affect the
predictions by jackard_max2_mean. As an illustration, Fig. 4,
shows three-way Venn diagrams of the sets of true and false
positives generated by the univariate models jackard_max2_mean,
str_max_prod and the multivariate model LR3 when the
specificity of each model was fixed at 0.95. As seen, nearly 88%
of the true positives (Fig. 4A) and 77% of the false positives (Fig. 4B)
generated by model LR3 are also generated by jackard_max2_-
mean. The remaining 12% of true positives and 23% of false
positives generated by LR3 were drug pairs having jackard_-
max2_mean slightly below its 95%-specificity threshold of 0.61
and generally high values of str_max_prod (Fig. 4C).
Possibly due to this domination by one predictor, the
multivariate models LR3 and GLM8 do not maximally leverage
the different types of information contained by the covariates. This
outcome is especially noticeable at very high specificity levels,
where, as reported earlier, the multivariate PPV was no higher
than the PPV produced by jackard_max2_mean. Since in real-
world prospective settings a predictive model would most likely be
used to generate a relatively small number of predictions that are
as reliable as possible, it is natural to ask whether other methods
for combining covariates could lead to improved PPV. One way to
increase the PPV would be to reduce the number of false positives
generated by the model. To achieve this reduction, a straightfor-
ward heuristic would be to set the training-set specificity of each
covariate at a very high level and to consider only those
predictions that are common to all covariates. To evaluate this
heuristic we set the prediction thresholds of jackard_max2_mean
and str_max_prod at their respective univariate 99
th percentiles in
the training set of non-edges (0.756 and 0.575) and generated a set
of 656 predicted drug pairs in the validation set that were above
both thresholds. We found that this set of predictions contained
134 true positives, with a corresponding PPV of 20.4% -
a substantial improvement over the multivariate models LR3
and GLM8.
Prediction of DDI Type
The present study is focused on the prediction of unknown
drug-drug interactions. The development of a robust method for
identifying specific AEs that may be associated with certain DDIs
is outside the scope of this work. For illustration purposes, we
conducted an initial investigation of a basic method for suggesting
potential types for the predicted DDIs. We used the ‘‘interaction
description’’ field in the Vantage Rx database, which describes the
type of interaction between two drugs. We investigated a straight-
forward method for predicting the DDI type associated with each
predicted interacting drug pair: we examined all other known
interactions involving either of these two drugs in the 2009
network (the ‘‘neighborhood types’’), and identified the most
common interaction types amongst them (see Methods for
complete details).
Fig. 5 illustrates the performance of this basic method on the set
of true positives predicted by the GLM model, with its specificity
fixed at 0.95. Of the 1,496 true positives predicted by the GLM
model, only 1,232 had a 2012 DDI type that existed among the
2009 neighborhood types. For each of these 1,232 drug pairs,
Fig. 5A shows the number of unique interaction types found in its
2009 network neighborhood and the rank of the true DDI type
when the ‘‘neighborhood types’’ were sorted in decreasing order of
frequency. The newly reported DDI types typically coincide with
one of the most frequently occurring types in the network
neighborhood. Fig. 5B enables a more precise description of this
phenomenon by plotting the cumulative distribution of the rank of
true ID. For instance, for 20% of the drug pairs, the true DDI type
was the most frequent neighborhood type, for 35% of the pairs,
Network-Based Prediction of Drug Interactions
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it was amongst the top 5. As an illustration, Table S5 shows five
top-ranked triples (drug, drug, DDI type) that were correctly
predicted by the above approach.
Discussion
The proposed multivariate model for predicting unknown drug-
drug interactions achieved an AUROC of 0.81 with a sensitivity of
0.48 given a specificity of 0.90. The model PPV was as high as
14%, corresponding to a ten-fold reduction in the search space of
possible DDIs. A heuristic approach aimed at reducing the
number of false positives resulted in a PPV of 20% and a fourteen-
fold reduction in the search space. Finally, a multivariate model
achieved AUROCs of 0.63, 0.81 and 0.92, respectively, for the
minor-DDI, major-DDI and contraindicated-DDI sub-networks.
These findings suggest that the proposed network method can be
useful for predicting future reported DDIs years in advance, and
that its predictive power is highest for the most severe DDIs. This
proposed approach can serve as a complementary hypothesis-
generation tool in supporting the work of drug safety professionals.
The proposed model included three types of covariates:
network, taxonomic and intrinsic. For the taxonomic and intrinsic
covariates, similarity in functional category or chemical structure
was positively correlated with the similarity of DDI profiles. For
network covariates, similarity in network neighborhoods was
positively correlated with similarity of DDI profiles. Overall, we
found that the 1
st order similarity-based covariates used in the
Figure 3. Predictive performance plots. (A) ROC curves for similarity-based covariates; (B) ROC curves for non-similarity covariates; (C) ROC
curves for multivariate models; (D) ROC curves for three severity-based DDI classes: minor, major and contraindicated.
doi:10.1371/journal.pone.0061468.g003
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th order
covariates, implying that network structure contains useful in-
formation for the prediction of unknown DDIs. We also found that
the non-similarity covariates displayed a marginal incremental
contribution when combined with the similarity covariates.
Tatonetti et al. [34] have recently published a non-network
based model for identifying DDIs for specific AEs. The present
study differs from Tatonetti et al.’s study in several ways. First, the
PPIN model is based on a drugome-level view of all DDIs, whereas
each of the models proposed by Tatonetti et al. focuses on the
DDIs associated with one specific AE. Second, the covariates in
the PPIN model are based on the network structure formed by the
known DDI relationships, whereas the covariates in Tatonetti
et al.’s models are not network-based (they are computed using the
AE frequencies from the Adverse Event Reporting System
(AERS)). Third, to assess the model’s predictive performance,
the current study uses a simulated prospective approach based on
two chronologically separated snapshots of a widely used DDI
database, whereas Tatonetti et al. used cross-validation within one
chronological snapshot as well as comparison with computation-
ally derived response variables.
This study has a number of limitations. The main limitation
relates to the fact that no perfect ‘‘gold standard’’ exists in the area
of drug safety. A number of studies in recent years have shown that
different safety databases often disagree about the existence and
the severity of drug-drug interactions [35–37]. The specific
reference standard used in this study contains all known drug-
drug interactions according to the compilers of the database, but
obviously does not contain interactions that have yet-to-be
discovered by the scientific community. Thus, it is not possible
to tell whether the pairs not reported as interactions are confirmed
true negatives or not-yet-known positives. Furthermore, the data
may contain DDIs that will subsequently be removed from the
database. Another limitation of the study is that it was conducted
on a subset of all marketed drugs determined by data availability.
Although this subset consisted of nearly nine hundred drugs, there
exists the possibility of a biased sample, implying that the results
would not necessarily hold for an even larger network of drug-drug
interactions. Further, the validation set for this study was the set of
all study-drug pairs not known to form an interaction in 2009.
Some of these pairs may consist of drugs that are never or rarely
prescribed together (for example, due to gender or age related
reasons). Such pairs can, however, be straightforwardly filtered out
by cross-referencing standard drug label information. As discussed
in the Results section, the LR and GLM modeling frameworks
proved satisfactory but sub-optimal for combining different
Figure 4. Model comparison. Analysis is based on predictions generated by the univariate models jackard_max2_mean, str_max_prod and the
multivariate model LR3 when specificity of each model was fixed at 95%. (a) Three-way Venn diagram of the true positives by the three models; (B)
Three-way Venn diagram of the false positives by the three models; (C) Scatter plot of jackard_max2_mean versus str_max_prod for the drug pairs
predicted to be DDIs by LR3 but not by jackard_max2_mean.
doi:10.1371/journal.pone.0061468.g004
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between the model covariates and the response variable can’t be
presumed due to the existence of potential confounders.
This study could be extended in several clinically important
directions, such as developing a rigorous model for generating
drug-drug-mechanism or drug-drug-AE predictions. Another
direction is to enrich the network data with frequency and severity
information on the reported DDIs to further improve predictive
performance. These extensions could increase the practical value
of the PPIN approach for drug-safety professionals. Due to the
‘‘gold standard’’ limitations mentioned earlier, a further un-
derstanding of the predictive value of the PPIN approach would be
achieved by applying it to reference data from other databases.
The proposed network-based DDI prediction method can be
put to immediate use, with practitioners training models using any
available clinical drug interactions database, and following up on
the highest scoring model predictions with thorough clinical
investigations. By augmenting the existing drug safety detection
tools with tools of drug safety prediction, drug interactions can be
identified earlier and more accurately, reducing drug-related
morbidity and mortality.
Materials and Methods
Network Construction
We constructed an integrated network representation of data on
drugs and drug-drug interactions. In this network, nodes denote
drugs and edges denote the known DDIs. The set of edges
corresponds to the DDIs contained in a 2009 snapshot of the
Vantage Rx database. For each drug in the network we assembled
the list of chemical substructures (from DrugBank) and a list of
ATC code(s). We refer to the network described above as the DDI
network. We then constructed three sub-networks of the DDI
network, namely those induced by the set of ‘‘minor’’, ‘‘major’’
and ‘‘contraindicated’’ DDIs, respectively. We refer to these three
networks as the minor-DDI, major-DDI, and contraindicated-
DDI sub-networks, respectively.
Predictive Modeling
The binary response variable Yij denoting the presence or
absence of an interaction between drug i and drug j was modeled
as a Bernoulli random variable and a function of three types of
covariates (Table S1): (i) Network – Covariates of the first type
depend on the structure of the observed DDI network but not on
the attributes of drugs; (ii) Taxonomic – Covariates of the second
type depend on the structure of the observed DDI network and on
the taxonomic attributes (i.e. ATC codes). As a preliminary step
for creating taxonomic covariates, we computed for every pair
(drug1, drug2) the minimum distance dATC(drug1, drug2), denoting the
minimum over all possible ATC positions of drug1 and drug2 of the
length of the shortest path between drug1 and drug2 in the ATC
taxonomy; (iii) Intrinsic – Covariates of the third type depend on
the structure of the observed DDI network and on the intrinsic
properties of drugs.
We began the model development by fitting all possible
univariate logistic regression (LR) models, to gauge the univariate
effect and significance of each covariate (Table S2). Next, we
developed multivariate LR models and performed a search to
optimize model fit (Akaike Information Criterion statistic) over all
possible subsets of covariates. The data used to estimate each LR
model consisted of the response variable Yij,i =1,…,855,
j=(i+1),…,856 and of the corresponding values of covariates Xijk
(where k=1,…,8 ranges over the final set of covariates) computed
from the 2009 DDI network. Thus, each pair of drugs (i, j) was
represented only once in the training data for the LR model. The
fitting of the LR model was carried out by maximum likelihood
estimation. The statistical significance (P values) of covariates was
assessed through the standard chi-square test in the LOGISTIC
procedure in the Statistical Analysis System (SAS), v9.2. After the
multivariate LR model was estimated, we computed the estimated
probability of interaction (or, score) pestij for each drug pair (i, j)i n
the validation set (the set of pairs that were non-edges in the 2009
DDI network). These model development and validation steps
were also carried out for the minor-DDI, major-DDI and
contraindicated-DDI sub-networks.
Finally, as a means of accounting for within-drug associations
among the responses Yij, we developed generalized linear mixed
(GLM) models, which consisted of the same fixed effects as the LR
models but included drug-specific random intercepts. The data
used to estimate the GLM8 model consisted of the response
variable Yij,i =1,…,856, j=1,…,856 and of the corresponding
values of covariates Xijk computed from the 2009 DDI network. In
Figure 5. Accuracy of DDI type prediction. Analysis is based on
DDI types occurring in the set of true positives predicted by the GLM
model when its specificity was fixed at 0.95. (A) The true positive pairs
are shown ordered according to the number of unique interaction IDs
found in the pair’s neighborhood (blue bars); the rank of each pair’s
true ID according to the 2012 snapshot (purple crosses) is also shown;
(B) Cumulative distribution of the rank of true ID.
doi:10.1371/journal.pone.0061468.g005
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training data, once as a response for drug i and a second time as
a response for drug j. This duplication was carried out to allow the
correct estimation of random intercepts. Note that if the random
intercepts were excluded from the model, the estimates of fixed
effects and probabilities of interaction would be identical to those
obtained earlier in the LR model. The fitting of the GLM models
was carried out by maximum likelihood using the adaptive
quadrature method in the GLIMMIX procedure in SAS v9.2
(Table S5). The ‘‘best linear unbiased predictor’’ (BLUP) was used
to estimate random intercepts. After the multivariate GLM model
was estimated, two estimated probabilities pestij and pestji were
generated for each drug pair (i, j) in the validation set: one based
on the fixed-effect estimates and the BLUP estimator for drug i
and another based on the fixed-effect estimates and the BLUP
estimator for drug j. Finally, we computed the predicted score for
each pair (i, j) by taking the arithmetic mean of the estimated
probabilities pestij and pestji.
We hypothesized that the validation set pairs having the highest
scores would be the ones that appear as true DDIs in the 2012
snapshot of Vantage Rx. To evaluate the predictive performance
we computed the validation set AUROC by comparing the scores
generated for validation set pairs with the actual presence or
absence of DDIs in the 2012 snapshot. In addition, we computed
the model sensitivity and positive predictive value for various
benchmark levels of specificity, including 0.99, 0.95 and 0.90.
Prediction of DDI Type
To suggest likely DDI types for the predicted interactions, we
employed the following straightforward method. For each
predicted DDI pair (i, j) we first identified all unique DDI types
corresponding to the set of edges having i or j as an end-point in
the 2009 DDI network, i.e. the DDI types occurring in the
network neighborhood of pair (i, j). Then, for each DDI type we
computed the neighborhood frequency count, i.e. the number of
times that type is encountered among the edges having i or j as an
end-point in the 2009 DDI network. We then sorted the
neighborhood types in decreasing order of frequency and
hypothesized that one of the most frequent neighborhood types
would coincide with the true DDI types observed in the 2012.
To evaluate the above method, we first identified the true
positives predicted by the GLM model when its specificity was
fixed at 0.95. For each such true positive we extracted the set of
2009 neighborhood interaction types sorted in decreasing order of
frequency count. We computed the rank of the true interaction
type (extracted from 2012 snapshot) within the set of neighbor-
hood types and the cumulative distribution of that rank.
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